HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cystadenoma

A benign neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. In some instances, considerable portions of the neoplasm, or even the entire mass, may be cystic. (Stedman, 25th ed)
Also Known As:
Cystadenomas
Networked: 476 relevant articles (9 outcomes, 42 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Neoplasms (Cancer)
2. Hemangioma (Angioma)
3. Tuberous Sclerosis (Bourneville's Disease)
4. Ascites
5. Carcinoma (Carcinomatosis)

Experts

1. Xie, Dan: 7 articles (10/2019 - 01/2005)
2. Kwiatkowski, David J: 6 articles (03/2015 - 10/2003)
3. Yang, Guo-Fen: 5 articles (10/2019 - 02/2009)
4. Yu, Yinhua: 5 articles (10/2013 - 10/2004)
5. Zeng, Yi-Xin: 5 articles (01/2013 - 01/2005)
6. He, Wei-Peng: 4 articles (11/2019 - 04/2010)
7. Liu, Jinsong: 4 articles (01/2014 - 10/2004)
8. Guan, Xin-Yuan: 4 articles (06/2010 - 01/2005)
9. Li, Chenggang: 3 articles (01/2023 - 01/2014)
10. Yu, Jane J: 3 articles (01/2023 - 01/2014)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Cystadenoma:
1. CateninsIBA
2. FH535IBA
3. DNA (Deoxyribonucleic Acid)IBA
4. Contrast MediaIBA
02/01/2012 - "Diagnosis of a biliary cystadenoma demonstrating communication with the biliary system by MRI using a hepatocyte-specific contrast agent."
01/01/2011 - "Biliary cystadenoma with bile duct communication depicted on liver-specific contrast agent-enhanced MRI in a child."
01/01/2011 - "We present a 9-year-old boy with biliary cystadenoma, diagnosed by MRI using a new liver-specific contrast agent (gadoxetic acid) that is eliminated by the biliary system. "
07/01/2000 - "Because the mucin secreted by biliary cystadenomas and cystadenocarcinomas causes filling defects and partial obstruction of contrast material at ERCP, MRCP is potentially more accurate in demonstrating the extent of these tumors. "
12/31/2009 - "hepatocellular carcinoma or liver metastasis) or infectious diseases; (3) For differentiation diagnosis between biliary cystadenoma and biliary cystadenocarcinoma; (4) To detect malignant change in Caroli's disease; (5) To depict the extent of Klatskin's tumor with greater clarity; (6) To make a distinction between gallbladder cholesterol polyp, adenoma and polypoid cancer; (7) To make a distinction between chronic cholecystitis with thickened wall and gallbladder cancer; (8) For differentiation diagnosis between motionless sludge and gallbladder cancer; (9) For differentiation diagnosis between common bile duct cancer and sludge or stone without acoustic shadowing; and (10) In patients who are suspected of having a drop of their percutaneous transhepatic cholangiodrainage tube, US contrast agent can be administered to through the tube detect the site of the tube."
5. SilverIBA
6. Atorvastatin (Lipitor)FDA Link
7. Imatinib Mesylate (Gleevec)FDA Link
8. gadolinium ethoxybenzyl DTPAFDA Link
9. 4-O-carboxymethylascochlorinIBA
10. Proteins (Proteins, Gene)FDA Link

Therapies and Procedures

1. Therapeutics
2. Hepatectomy
3. Pancreaticoduodenectomy
4. Surgical Portacaval Shunt (Portacaval Anastomosis)
5. Laparotomy